Table 2.

Summary of Randomized Control Trials (RCT) for Evaluating HCQ for COVID-19 Treatment.

Study Design Pts Study Groups Results: Primary/Secondary Outcomes Methodological Issues
RCT24 150 1. HCQ
2. SOC		 No Sig.Dif. in virological cure rates at day 28 Open-label study
RCT23 30 1. HCQ
2. SOC		 Primary Outcome
  • No Sig.Dif. in virological cure rates (HCQ 86.7% vs SOC 93.3%; P>0.05)
Secondary Outcome
  • No Sig.Dif. for time to body temperature normalization and improvement in follow-up examinations
  • Published only in Chinese
  • Small-scale study
Preliminary data from RCT22 4674 1. HCQ
2. SOC		 Primary Outcome
  • No Sig.Dif. in survival rates at 28 days (25.7% vs 23.5% in treatment versus SOC, HR 1.11 [95% CI 0.98–1.26]; P=0.10)
Secondary Outcome
  • No impact of HCQ Tx on length of hospitalization
 Preliminary results; not yet peer-reviewed
RCT25 667 1. HCQ
2. HCQ+AZ
3. SOC		 Primary Outcome
  • No clinical status benefit at 15 days
Secondary Outcome
  • No mortality benefit
  • For HCQ Pts and HCQ+AZ: Increased incidence of QTc prolongation and elevated liver enzymes in both treatment groups when compared to SOC

AZ, azithromycin; CI, confidence interval; HCQ, hydroxychloroquine; HR, hazard ratio; Sig.Dif., significant difference(s); SOC, standard of care.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2020 July; 11(3): e0025. ISSN: 2076-9172
Published online 2020 July 31. doi: 10.5041/RMMJ.10416
Copyright: © 2020 Rakedzon et al.